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Deregulation of ErbB signaling plays a key role in the progression of multiple human cancers. To
help understand ErbB signaling quantitatively, in this work we combine traditional experiments
with computational modeling, building a model that describes how stimulation of all four ErbB
receptors with epidermal growth factor (EGF) and heregulin (HRG) leads to activation of two critical
downstream proteins, extracellular-signal-regulated kinase (ERK) and Akt. Model analysis and
experimental validation show that (i) ErbB2 overexpression, which occurs in approximately 25%
of all breast cancers, transforms transient EGF-induced signaling into sustained signaling, (ii) HRG-
induced ERK activity is much more robust to the ERK cascade inhibitor U0126 than EGF-induced
ERK activity, and (iii) phosphoinositol-3 kinase is a major regulator of post-peak but not pre-peak
EGF-induced ERK activity. Sensitivity analysis leads to the hypothesis that ERK activation is robust
to parameter perturbation at high ligand doses, while Akt activation is not.
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Introduction
The ErbB signaling network, a major player in tumorigenesis,
comprises the following: multiple extracellular ligands; the
four trans-membrane receptors ErbB1 (EGFR), ErbB2 (HER2/
NEU), ErbB3, and ErbB4; cytoplasmic adapters, scaffolds,
enzymes, and small molecules. Signaling is initiated when
ligand binds to a receptor and causes the receptors to homo- or
heterodimerize. Receptor dimerization activates the receptor’s
tyrosine kinase domain, which leads to autophosphorylation
of tyrosine residues on receptor cytoplasmic tails. Multiple
cytoplasmic adapter, scaffold, and enzymatic proteins are then
recruited to the plasma membrane by binding to receptor
phosphotyrosines. A complex network of interactions between
the activated receptors, recruited proteins, and plasma mem-
brane molecules eventually culminates in the activation of
multiple downstream effectors, including extracellular-signal-
regulated kinase (ERK) and protein kinase B/Akt, which are
implicated in the control of proliferation and survival.
Abnormalities within the ErbB signaling network correlate
with the development of several cancer types, and multiple
drugs that target these defects have been used to treat cancer
successfully (Yarden and Sliwkowski, 2001). For example, in
the approximately 25% of patients whose metastatic breast
cancer overexpresses the ErbB2 receptor, median patient
survival time is improved by administering the ErbB2-
targeted, monoclonal antibody trastazumab (Hortobagyi,
2001). Although knowledge of some specific ErbB signaling
network defects associated with tumorigenesis has led to the
development of successful cancer treatments, these targeted
treatments are rarely ‘magic bullets’. Furthermore, there are
instances where potentially drug-sensitive cancers either do
not respond and/or eventually become resistant to treatment
(Robinson et al, 2006). Improving the efficacy of these targeted
treatments requires a more detailed understanding of the
mechanisms by which cancer-correlated network properties
cause deregulation of the entire ErbB signaling network.
Spatio-temporal signaling aspects play a key role in the ErbB
network’s control of cell fate, as different inputs stimulate
different activation kinetics, which ultimately lead to different
cell fates. For example, in AU565 cells, stimulation with the
ligand heregulin (HRG) causes sustained network activation
and leads to differentiation (Lessor et al, 1998); in PC12 cells,
stimulation with the ligand epidermal growth factor (EGF)
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causes transient network activation and leads to proliferation
(Marshall, 1995). In MCF-7 cells, Thottassery et al (2004)
showed that EGF and HRG cause transient and sustained
network activation, respectively. Although it is clear that (i)
different ErbB ligands can stimulate different network activa-
tion dynamics, and (ii) that there is a connection between
ligand-dependent activation kinetics and cell fate, to under-
stand how the ErbB signaling network controls cell fate,
we must first elucidate the mechanisms that control
ligand-dependent activation kinetics. Similarly, understanding
ligand-dependent signaling mechanisms is a key step in
understanding how the ErbB network’s deregulation contri-
butes to tumorigenesis.
Because the ErbB signaling system is a highly intercon-
nected, dynamic network containing multiple feedback loops,
it is difficult to predict the response of the network solely
by qualitative means. It is becoming increasingly clear that
quantitative methods are required to understand the mechan-
isms by which signaling networks function. Therefore, in this
work, we take a combined experimental and computational
model-based approach to understand the ErbB network that
was pioneered by Kholodenko et al (1999), and expanded
upon by Schoeberl et al (2002), Hatakeyama et al (2003),
Hendriks et al (2003), Resat et al (2003), Blinov et al (2006),
Shankaran et al (2006), and many others. This approach
employs a combination of mechanistic, ordinary differential
equation (ODE) modeling (for simulation) with quantitative
immunoblotting (for experimental measurements of signaling
dynamics).
Current methods for dynamic modeling of the interactions
between proteins that contain multiple phosphorylation sites
and binding domains requires dealing with a combinatorial
explosion of potential species, significantly complicating the
development and simulation of signaling network models. For
example, a mechanistic description of the ErbB1 receptor that
simultaneously accounts for the ligand-binding domain, the
dimerization site, the kinase domain, and 10 phosphorylation
sites requires more than 106 differential equations. This
phenomenon, referred to as ‘combinatorial complexity’, is a
fundamental problem in developing mechanistic, differential
equation models of signal transduction networks (Goldstein
et al, 2004; Blinov et al, 2006). Due to combinatorial com-
plexity, previous models of ErbB signaling were either limited
to a single ErbB receptor and ligand (Kholodenko et al, 1999;
Schoeberl et al, 2002; Hatakeyama et al, 2003) or only
accounted for complexity at the level of ligand binding and
receptors (Hendriks et al, 2003, Shankaran et al, 2006). Here,
we develop a novel technique for handling the problem of
combinatorial complexity, allowing us to incorporate a greater
number of ErbB network entities than in previous models.
Using a combined quantitative modeling and experimental
approach, in the current work we investigate the short-term
(p30 min) response of the key ErbB signaling network
intermediates ERK and Akt to stimulation with the EGF and
HRG ligands, in MCF-7 breast cancer cells. We build a model
to represent the measured dynamics of ligand-dependent ErbB
network activation, use the model to generate hypotheses
about the control of ERK and Akt activation, and experimen-
tally corroborate the prediction that EGF-induced ERK activity
is much more sensitive than HRG-induced ERK activity to the
ERK cascade inhibitor U0126. Through model analysis, we find
that control of ERK and Akt activation is distributed among
many cellular mechanisms, and the responsible mechanisms
change as a function of time and ligand dose combinations.
Results
Model formulation
To help understand ErbB network signaling, we developed a
computational model that relates EGF and HRG stimulation of
the ErbB receptors to activation of ERK and Akt. It is an ODE
model that consists of two compartments (extracellular and
cytoplasmic), 117 species, 235 parameters, and 96 (net)
reactions (details of the rate equations, parameter values,
and parameter estimation procedures can be found in the
Supplementary information online). The model, although
reasonably large, is not a combinatorially complex, in silico
replica of all potential distinct biochemical species and
processes. Such a microscopically comprehensive model
would be impractical to develop, both computationally and
experimentally. The goals for this model are to reflect the
experimental data measured in this study to help provide
insight into mechanisms that drive the observed phenomena.
In this regard, our goals are similar to the goals of those
who developed previous models of ErbB signalling. A
simplified schematic representation of the model structure is
shown in Figure 1, the reaction network is shown in Figure 2,
and the model is described as follows.
Ligand binding and dimerization
EGF has high affinity for ErbB1, HRG has high affinity for both
ErbB3 and ErbB4, and no natural ligand is known for ErbB2.
Ligand-bound ErbB1, ErbB3, and ErbB4 can dimerize with
other ligand-bound ErbB1, ErbB3, or ErbB4, whereas ErbB2 is
constitutively dimerization prone. Because ErbB2 is constitu-
tively dimerization competent, it typically is referred to as the
preferred dimerization partner in the ErbB family and tends to
form heterodimers with other ErbB family members (Graus-
Porta et al, 1997). Therefore, ligand-bound ErbB1, ErbB3, and
ErbB4 and free ErbB2 can form homo- and/or heterodimers
that consist of 1-1, 1-2, 2-3, 2-4, 3-4, 4-4, 1-3, and 1-4 receptors.
ErbB dimers 
EGF/HRG
Plasma membrane 
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Figure 1 Simplified schematic representation of the ErbB signaling model.
ErbB receptor ligands (EGF and HRG) activate different ErbB receptor dimer
combinations, leading to recruitment of various adapter proteins (Grb2, Shc,
and Gab1) and enzymes (PTP1-B, SOS, and RasGAP). These membrane
recruitment steps eventually lead to the activation of ERK and Akt.
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We neglect 3-3 dimers, because Berger et al (2004) showed that
these dimers do not form, and further, ErbB3 receptor is kinase
dead (Citri et al, 2003). To our knowledge no studies have
shown that ErbB2 homodimers will initiate significant levels of
signaling in the absence of other ErbB receptors. However,
wild-type ErbB2 can form a small population of homodimers,
and the E664V mutation found in some ErbB2-dependent
cancers can cause a large amount of ErbB2 homodimers to
form (Burke et al, 1997). In cells bearing this mutation, ErbB2
homodimers may be important to consider, as ErbB2 homo-
dimerization might represent a sequestration mechanism that
combats ErbB2 overexpression. However, MCF-7 cells are
estrogen receptor positive (indicative of early stage breast
cancers), do not depend on or overexpress ErbB2, and we are
unaware of any experimental evidence to indicate that the
E664V mutation associated with later-stage, ErbB2-dependent
breast cancers is present in MCF-7 cells. As Burke et al
(1997) showed that only approximately 5% of all wild-type
ErbB2 dimers exist in oligomeric form, sequestration of ErbB2
through homodimerization should have minimal impact on
Figure 2 Reaction network diagram of the ErbB signaling model. Net reaction rates are labeled according to their index. Double-sided line-head arrows depict
reversible binding reactions. Single-sided solid-head arrows with solid lines depict chemical transformation, while those with dotted lines depict a potentially multistep
chemical reaction process. Single-sided double solid-head arrows depict summation into a S-state. (A) Ligand binding, receptor dimerization, receptor
autophosphorylation, and primary receptor binding. (B) Membrane recruitment and phosphorylation of intermediate signaling proteins. S-states are summations over
specific membrane-localized species with identical downstream signaling activity and membrane-anchorage. Detailed explanations S-states can be found in Table I and
the main text. (C) PTP-1B-mediated dephosphorylation reactions. (D) PIP3-mediated Akt activation. (E) Ras-mediated ERK activation. (F) ERK-mediated feedback. E,
EGF; H, HRG; Ei, ErbBi; EijX, ErbB homo- or heterodimer bound to protein X; G, Grb2; S, Shc; I, PI-3K; T, PTP-1B; O, SOS; A, Gab1; R, RasGAP; RsD, Ras-GDP; RsT,
Ras-GTP; P2, PIP2; P3, PIP3; P denotes tyrosine phosphorylation, PT denotes threonine/serine phosphorylation, and *denotes activation.
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signaling in MCF-7 cells, and therefore we neglect 2-2
homodimers.
Receptor dimer autophosphorylation and the ‘virtual
phosphorylation site’
Once a receptor dimer is formed, it gains tyrosine kinase
activity and can autophosphorylate on several tyrosine
residues. Simultaneously accounting for all these phosphor-
ylation sites results in a combinatorial explosion of potential
species, thus, we represent all autophosphorylation sites as a
single ‘virtual phosphorylation site’ as similar to previous
models of ErbB signaling (e.g. Kholodenko et al, 1999). To
reduce the model in this manner, we must assume that that
either all or no sites are phosphorylated at a particular time.
This assumption may be close to reality, as the phosphory-
lation and dephosphorylation steps are fast relative to down-
stream events. Phosphorylation is fast because the receptor
cytoplasmic tails (substrate) are tethered to the dimer (kinase),
concentrating substrate and enzyme in an extremely small
volume. Because the tyrosine phosphatase PTB-1B is recruited
to ErbB receptor dimers and activated in a ligand-dependent
fashion (Liu and Chernoff, 1997), it is also likely that dephos-
phorylation is fast. Also supporting this assumption, auto-
phosphorylation sites on ErbB1 and ErbB2 show very similar
phosphorylation dynamics in human mammary epithelial
cells (HMECs) in response to EGF and HRG (Wolf-Yadlin et al,
2006), and autophosphorylation sites on ErbB1 show very
similar phosphorylation kinetics in HeLa cells in response to
EGF (Schulze et al, 2005).
Membrane recruitment and ligand-induced
degradation
Membrane recruitment of signaling proteins to the plasma
membrane is an early step of signal propagation through the
ErbB network, and is critical for signal propagation, because it
colocalizes key network enzymes (Kholodenko et al, 2000).
Following receptor phosphorylation, we consider that the
proteins Shc, Grb2, phosphoinositol-3 kinase (PI-3K), PTP-1B,
and RasGAP are recruited by binding directly to tyrosine-
phosphorylated receptors. We assume that PI-3K cannot bind
directly to ErbB1 or ErbB2 (Citri and Yarden, 2006). The
proteins SOS and Gab1 are secondary recruits, and have
proline-rich domains (PRD), which bind to the N-terminal or
C-terminal Src homology 3 (SH3) domains of Grb2, respec-
tively (Figure 3). Gab1 can also be recruited to the membrane
via its pleckstrin homology (PH) domain binding to PIP3
(Figure 3). Following membrane recruitment, Shc, RasGAP,
and Gab1 are tyrosine phosphorylated by receptor dimers,
and then Shc and Gab1 can recruit additional downstream
proteins. We represent the multiple Gab1 tyrosine phosphory-
lation sites as a virtual phosphorylation site.
ErbB1 homodimers undergo rapid EGF-induced internaliza-
tion and subsequent degradation through a multistep process,
whereas other dimers stay much longer at the plasma mem-
brane (Sorkin et al, 1993; Baulida et al, 1996). For this model,
we approximate the rate of ligand-induced 1-1 dimer degrada-
tion as a first order process, which is reasonable as the initial
internalization and recycling steps are fast relative to the
subsequent degradation step (Wiley, 2003) (see Supplementary
information online for derivation).
Reducing the complexity of membrane recruitment
The receptor cytoplasmic tails, which contain the tyrosine
phosphorylation sites, are of similar size to their downstream
binding proteins, and the tyrosine phosphorylation sites
considered on Gab1 are in close proximity. It is therefore
likely that steric hindrance will interfere with the simultaneous
binding of more than one adapter protein to a virtual
phosphorylation site. Thus, we represent binding to virtual
sites as fully competitive (mutually exclusive) between all
downstream proteins. The complement of binding sites that
comprise each virtual phosphorylation site can be found
in the Supplementary information online. If a virtual phos-
phorylation site contains more than one actual site that is
capable of recognizing a downstream protein (e.g. ErbB3 has
multiple PI-3K binding sites), the binding on-rate of the
downstream protein to the virtual site should be multiplied by
the number of sites it can potentially bind, a factor we term the
on-rate multiplier (Supplementary information online).
We assume that tyrosine-phosphorylated Shc, RasGAP, and
Gab1 are concentrated in a relatively thin layer near the
membrane, where their ErbB kinases are localized (Brown
and Kholodenko, 1999). Once these phosphorylated proteins
dissociate from the membrane, they are rapidly dephosphory-
lated; therefore, we neglect the concentration of these phos-
phorylated forms in the cytoplasm. We also do not consider the
double membrane recruitment of Grb2 or Gab1. For example,
we neglect that Gab1 membrane-bound through its PH
domain can simultaneously bind via its C-terminal SH3
domain to membrane-bound Grb2 (although we do consider
that this same Gab1 can recruit free Grb2 through its PRD). As
only one of these binding events is sufficient for membrane
pY
N-term
SH3 
SH2 
C-term
SH3
SOS
PRD
GAB1
PRD
SH2 
PRD PH
domain
SH3 PIP3Virtual
pY site
Grb2
Gab1
B
Figure 3 Composition of the multi-domain proteins (A) Grb2 and (B) Gab1.
Grb2 has C- and N-terminal SH3 domains that bind to Gab1 and SOS,
respectively, and an SH2 domain. GAB1 has a PH domain, a PRD, and several
tyrosine phosphorylation sites. SH3 domains bind to proline-rich domains, PH
domains bind to phospholipids such as PIP3, while SH2 domains bind to
phosphotyrosine. SH3, Src homology 3; SH2, Src homology 2; PH, Pleckstrin
homology; PRD, proline-rich domain; pY: phosphotyrosine.
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recruitment, accounting for both membrane localizing binding
events simultaneously should have a small effect on down-
stream signaling.
Membrane recruitment is mediated by specific binding reac-
tions between multiple network entities, and it results in the
formation of several large multi-protein complexes. Account-
ing for the microscopic details of all these large membrane
complexes creates a combinatorial explosion of potential
species. To reduce this complexity, we assume that for
propagating signals, the route of membrane recruitment does
not affect the action of the recruited protein. For example, we
assume that it is not important whether Grb2 is bound to
different receptor dimers or to tyrosine-phosphorylated Shc
(the route of membrane recruitment), all that matters is that
Grb2 is at the membrane such that it can recruit downstream
proteins. Mathematically, we assume (in this example) the rate
law describing how downstream proteins bind to Grb2 is
identical regardless of how Grb2 is recruited to the membrane.
This assumption allows us to reduce model complexity by
defining lumped, membrane-localized states (denoted by S)
that are sums over plasma membrane-localized proteins that
have identical downstream signaling action. The definitions of
membrane-localized states can be found in Table I, and
lumping is depicted by double solid-head arrows in Figure 2.
To use thisS-approach, we must modify traditional methods
of modeling. First, ‘seeding’ species that undergo subsequent
binding or modification (e.g. EijG) represent a mosaic of
different membrane-bound states. Consequently, these seeding
species cannot be used in moiety conservation calculations
for adapter and scaffold proteins. Moiety conservation is
determined by adding all membrane-localized S-states and
free states (Supplementary information online). Second, we
must change the driving force for dissociation reactions of
seeding species. For example, dissociation of E11G cannot be
driven by the concentration of E11G, because other things
could have bound to the G. Therefore, we multiply the
dissociation driving force concentration by a fraction that
represents the amount of the particular membrane-bound
species that has not been subsequently modified (Supplemen-
tary information online).
Downstream signaling and feedback
The main effects of membrane localization of recruited
proteins are dephosphorylation of phosphotyrosines by PTP-
1B, production of PIP3 by PI-3K, which leads to Akt activation,
and conversion of Ras-GDP to Ras-GTP by SOS, which leads to
Raf, MEK, and ERK activation. Ras-GTP is converted back to
Ras-GDP by both RasGAP and phosphorylated RasGAP, and
PIP3 is converted back to PIP2 by PTEN. To reduce model
complexity, when appropriate, we describe complex yet
sequential multistep processes, such as the activation of Raf
by Ras and Akt by PIP3, as a single, semimechanistic step.
Because the condensed multistep processes are sequential,
these simplifications allow the reduced model to retain the
original network topology. However, these simplifications
necessarily require us to describe the simplified steps empirically.
Whether a reduced, one-step description is appropriate or
not depends on if the activation mechanism is processive or
distributed. In processive mechanisms, the substrate does not
dissociate and rebind the enzyme between intermediate
activation steps, and therefore a reduced, one-step mechanism
using a Michaelis–Menten rate law is adequate in these cases.
In distributed mechanisms, the substrate dissociates and
rebinds the enzyme between catalysis steps, and this can lead
to potential ultrasensitivity and bistability (Markevich et al,
2004). As it is known that the activation of ERK by MEK
follows a distributed mechanism (Zhao and Zhang, 2001), we
use a full, mass action description for ERK activation. In the
absence of evidence for a distributed mechanism, we use a
simplified, one-step description.
Although it is clear that internalized 1-1 homodimers can
initiate signaling (Wiley, 2003), we do not explicitly distin-
guish between signaling from the plasma membrane and
internalized 1-1 dimers. Thus, the 1-1 homodimer states in the
model represent a sum over internalized and plasma
membrane receptors. However, there is evidence that PI-3K
cannot signal from endosomes due to lack of PIP2 (Haugh
and Meyer, 2002). To account for this phenomenon yet keep
from significantly increasing model complexity, we define
an empirical, time-dependent parameter that represents the
endosomal fraction of ErbB1 receptors that have indirectly
recruited PI-3K. This parameter is represented by a general
first order system, and the details are in the Supplementary
information online. We then exclude this fraction of PI-3K from
converting PIP2 to PIP3.
Activated ERK mediates multiple modes of negative feed-
back. Activated ERK can inactivate SOS (Dong et al, 1996) and
Gab1 (Lehr et al, 2004) by direct phosphorylation. Addition-
ally, many literature studies show that activated ERK
phosphorylates the ErbB1 receptor by direct phosphorylation
Table I Description of membrane-localized S-states
S-State Description
SG Grb2-containing species in which the Grb2 SH2 domain is
bound to tyrosine-phosphorylated receptor dimer (EijP) or
to tyrosine-phosphorylated Shc (SP), and both Grb2 SH3
domains are unbound.
SS Shc-containing species in which the Shc SH2 domain is
bound to tyrosine-phosphorylated receptor dimer (EijP)
or to membrane-localized, tyrosine-phosphorylated GAB1
(AP), and Shc is unphosphorylated.
SI PI-3K-containing species in which PI-3K is bound to
tyrosine-phosphorylated receptor dimer (EijP) or to
membrane-localized, tyrosine-phosphorylated GAB1 (AP).
SR RasGAP-containing species in which RasGAP is bound
to tyrosine-phosphorylated receptor dimer (EijP) or to
membrane-localized, tyrosine-phosphorylated GAB1 (AP),
but is not phosphorylated.
ST PTP-1B-containing species in which PTP-1B is bound to
tyrosine-phosphorylated receptor dimer (EijP) or to
membrane-localized, tyrosine-phosphorylated GAB1 (AP).
SA GAB1-containing species in which the GAB1 PH domain
is bound to PIP3 or the PRD is bound to Grb2, and GAB1
is unphosphorylated.
SO SOS-containing species that are bound to a membrane-
localized N-terminal SH3 domain of Grb2.
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of T669 (e.g. Northwood et al, 1991; Sanghera et al, 1992), and
that this can lead to decreased receptor internalization and
substrate specificity (Heisermann et al, 1990) and can mediate
decreased kinase activity (Takishima et al, 1988). Therefore,
we allow for the possibility that ERK can phosphorylate ErbB1,
causing protection from degradation and decreased kinase
activity. Interestingly, this threonine site and the motif
recognized by ERK (PLTP) is conserved on ErbB2 and ErbB4,
but not on ErbB3. Therefore, we also allow for the possibility of
ERK phosphorylation of ErbB2 and ErbB4.
Dynamic and dose response of the ErbB signaling
network to EGF and HRG
Investigation of any dynamic system begins with input
perturbations followed by monitoring of system variables.
Therefore, we made different magnitude step changes in the
concentrations of EGF and HRG and observed the dynamic
response of multiple components of the ErbB signaling
network. We constrain our study to the first 30 min of signal-
ing, as past this point immediate early gene responses begin to
become important in determining the network activation state.
Until such responses are mechanistically well understood, it
will be difficult to build a model that can describe signaling
past 30 min. However, even if the immediate early gene
responses are well understood, it will still be a technically
difficult task to model this next layer of complexity.
Experimental results along with model simulations are
shown in Figure 4. Overall, the model simulations show excel-
lent quantitative and qualitative agreement with the experi-
mental data, although the model slightly overpredicts 30-min
ERK activity. We think this may be due to not incorporating
the immediate early gene expression response of MKP1, which
is an ERK phosphatase known to be upregulated in response
to EGF within 30 min (Brondello et al, 1997). Adding such
a mechanism is out of the scope of this paper and we are
presently working on such a model.
Figure 4A and B show results from simultaneous stimulation
with both EGF and HRG. At constant HRG stimulation,
increasing EGF slightly increases the response of both ERK
and Akt. In contrast, at constant EGF stimulation, increases
in HRG cause a large increase in ERK and Akt activation,
and notably, make the signaling more sustained. The effect
that HRG has on EGF signaling is more pronounced at low
EGF doses. These data collectively show that HRG acts as a
dominant ligand, that is, when both HRG and EGF are present,
the downstream signaling resembles that of HRG.
Figure 4C shows the results when the EGF and HRG
responses are compared directly. We see that globally HRG
stimulates higher peak and more sustained activation of Shc,
MEK, ERK and Akt. However, both model simulations and
experimental data show that EGF-induced 5-min ERK activation
is approximately 80% of the HRG-induced value, whereas EGF-
induced MEK activation is only approximately 50% of the HRG-
induced value. This suggests that HRG stimulates excess MEK
activation above what is needed for peak ERK activation, and
leads us to hypothesize that HRG-induced ERK activity should
be less sensitive to a MEK inhibitor than EGF-induced ERK
activity. We test this hypothesis experimentally, and the results
are presented in a subsequent section of the current study.
Model parameter sensitivity analysis generates
novel hypotheses as to the dominant mechanisms
for ERK and Akt activation
To begin to understand the behavior of this complex system, we
performed linear sensitivity analysis by making a 1% change in
each model parameter and looking at the fractional effect on
each observable. (This analysis is analogous to calculating the
control coefficients and response coefficients in metabolic
control analysis; e.g. Hornberg et al, 2005). The results from this
analysis contain a wealth of information about how the ErbB
signaling network might be functioning in MCF-7 cells, and the
full parameter sensitivity matrix can be found in the Supple-
mentary information online. Here, we focus our efforts on
investigating the mechanisms that may be controlling the peak
(5-min) and long-time (30-min) activation of ERK and Akt at
different dose combinations, and these results are shown in
Table II. Although Table II contains many results that are to be
expected (e.g. parameters directly affecting PIP2/PIP3 conver-
sion control Akt activity and parameters directly affecting Ras,
Raf, and MEK activation control ERK activity), we find that there
are several non-obvious results, which we elaborate on below.
ERK activation is robust to parameter perturbation at
high ligand doses, whereas Akt activation is not
This statement is evident by observing the magnitude
of parameter perturbation effects at 10 nM EGF, 10 nM HRG,
and 10 nM EGF with 10 nM HRG (Table II). For ERK, at both
short and long time points, the majority of the top positive and
negative sensitivity coefficients are well below 0.01 (10 nM
EGF-stimulated 30 min ERK activation to a lesser extent than
the others). This indicates that the parameters with the
greatest effect on ERK activation can be changed by significant
amounts without having a large impact. On the other hand, for
Akt, the largest sensitivities are well above 0.01, indicating that
small changes in these parameters can cause large changes in
Akt activity. This difference in robustness to parameter
variation may be due to the involvement of ERK in multiple
negative feedback loops, and the absence of such feedback
from Akt. It is well known from control theory that negative
feedback endows a system with robustness to disturbances
(Ogunnaike and Ray, 1994; Freeman, 2000).
An alternative way to interpret robustness properties of a
particular quantity from sensitivity analysis is to evaluate
statistics of the sensitivity coefficient ‘population’ (Table III).
If the mean of the population is close to or essentially zero
(in this case |/SS|  0.01), then a small standard deviation
is indicative of robustness, as most sensitivity coefficients will
then be close to zero. Again if the mean of the population is
essentially zero, then a high kurtosis (the 4th moment; a
measure of the ‘peakedness’ of the distribution around the
mean) is also indicative of robustness. High kurtosis indicates
that the majority of the sensitivities are clustered tightly
around the mean, with more of the variance due to large,
infrequent deviations rather than moderate, frequent devia-
tions. Interestingly, a higher kurtosis gives a higher probability
that a sensitivity with extreme deviation from the mean will
occur, indicating that although a particular quantity may be
robust to many perturbations, it may be very fragile to a few.
This interpretation of kurtosis is also in line with the current
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Figure 4 Dynamic and dose response of the ErbB signaling network in MCF-7 cells. Data were normalized as described in Materials and methods. (A) ERK activation
in response to simultaneous EGF and HRG stimulation. (B) Akt activation in response to simultaneous EGF and HRG stimulation. (C) Comparison of EGF and HRG
responses for various network nodes.
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thinking that there is an inevitable tradeoff between robust-
ness and fragility (Kitano, 2004). We see from Table III that
these statistical interpretations corroborate the arguments
presented above that ERK activation is robust at high ligand
doses, whereas Akt is not, and additionally represent a simple
and quick way to evaluate robustness.
PI-3K is a dominant factor for post- but not pre-peak
EGF-induced ERK activation
For both low and high doses of EGF, Table II shows that PI-3K is a
dominant-positive factor for 30 min ERK activation but not for
5 min ERK activation. This implies that EGF-induced ERK
activity is controlled by different cellular mechanisms at different
times; the descending portion (post-peak) but not the rising
portion (pre-peak) of the response curve is highly dependent on
PI-3K activity. This phenomenon is due to degradation of active
1-1 homodimers. At short times, there are still many 1-1
homodimers that can signal to ERK, however, as time progresses
these homodimers are degraded, and therefore signaling to ERK
must rely on alternative mechanisms at longer times. In this case,
an alternative mechanism is the PI-3K-PIP3-Gab1 pathway. We
note that this conclusion is not sensitive to the time-dependent,
non-mechanistic parameter that characterizes the amount of
ErbB1 in endosomes incapable of signaling through PI-3K.
Modeling analysis of the multiple negative
feedback loops
There are multiple negative feedback loops incorporated into
the model, and with the exception of ligand-induced degrada-
tion, it is not obvious what distinct roles, if any, these feedback
loops may play in regulating ligand-dependent signaling. To
investigate the potential roles of these various negative
feedback loops, we inhibited these feedbacks in silico and
Figure 4 Continued.
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observed the predicted ERK and Akt activation at different
ligand doses (Figure 5). As negative feedback loops are being
inhibited, we expected that ERK and Akt activity should
always increase. However, Figure 5 shows that this is not
always the case. Most notably, ERK negative feedback to
receptors (Figure 5B) positively affects EGF-induced peak ERK
and Akt activity. Further simulations suggested that this is
because ERK inhibits ErbB2 less than ErbB1, manifested as
decreased RasGAP membrane recruitment mediated by a shift
toward more 1-2 heterodimers rather than 1-1 homodimers.
While simulations predict that PTP1-B is the dominant-
negative feedback for Akt signaling (Figure 5A) with ERK-Gab
feedback (Figure 5D) and ligand-induced degradation
(Figure 5F) playing a smaller role, there is no dominant feed-
back controlling ERK signaling; it differs based on time and
dose combination. Long-term, EGF-induced ERK signaling is
mainly controlled by ERK receptor feedback (Figure 5B) and
ligand-induced degradation (Figure 5F), short- and long-term
HRG-induced signaling is mainly controlled by RasGAP
phosphorylation (Figure 5E) and to a lesser extent the ERK-
SOS feedback (Figure 5C) and ERK-Gab feedback (Figure 5D).
Such distributed control of ERK activity makes it a very versa-
tile signaling entity for the cell, being finely tunable in many
different ways, perhaps explaining, in part, why ERK is impor-
tant in so many different signaling systems.
Model predictions, validation, and limitations
ErbB2 overexpression sustains EGF signaling
The above model analyses allowed us to gain general
understanding of the ligand-dependent control of ERK and
Akt activity. While this general understanding is valuable by
itself, understanding how known, cancer-correlated network
abnormalities affect signaling is of primary and immediate
interest. We used the model to investigate how such a network
abnormality, ErbB2 overexpression, which occurs in approxi-
mately 25% of breast cancer, would affect the dynamics of ERK
and Akt activation, and the results are shown in Figure 6A.
ErbB2 overexpression is not predicted to cause significant
changes in HRG signaling, whereas ErbB2 overexpression
leads to more sustained EGF signaling, while leaving peak
ERK activation unaffected and actually decreasing peak Akt
activation. This model prediction qualitatively and quantita-
tively agrees with the data of Wolf-Yadlin et al (2006) and
Kumar et al (2007), which shows that at 10 and 30 min after
EGF stimulation, ERK activation is between 1.15- and 2-fold
higher for HMECs overexpressing ErbB2. The agreement
between our model prediction and an independent data set
gives a strong point of model validation.
As ErbB2 overexpression shifts the receptor dimer distribu-
tion toward more 1-2 heterodimers rather than 1-1 homo-
dimers and only 1-1 homodimers undergo ligand-induced
degradation, the more sustained EGF-signaling is expected.
However, the predicted decrease in peak Akt signaling is not
expected, as any increase in receptor abundance should lead to
increased signaling. Looking at the kinetic scheme and model
parameters, we hypothesized that this phenomenon might be
due to increased recruitment of PTP1-B by 1-2 heterodimers,
as 1-2 heterodimers had a slightly higher predicted affinityTa
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for PTP1-B than 1–1 homodimers. We therefore performed
simulations where the rate constants for reaction 74 (PTP1-B
binding to 1-2 heterodimers) were set equal to the rate cons-
tants for reaction 73 (PTP1-B binding to 1-1 homodimers),
and the results are shown in Figure 6B. We found that under
these conditions ErbB2 overexpression then increases peak
Akt activation.
HRG-stimulated ERK activation is more robust than
EGF-stimulated ERK activation to the MEK inhibitor
U0126
The experimental and simulation data in Figure 4C show that
both EGFand HRG induce similar peak ERK activation, but the
magnitude of peak MEK activation is much smaller for EGF.
Table III Sensitivity coefficient population statistics
EGF=0.5 nM;
HRG=0 nM
EGF=10 nM;
HRG=0 nM
EGF=0 nM;
HRG=0.5 nM
EGF=0 nM;
HRG=10 nM
EGF=0.5 nM;
HRG=0.5 nM
EGF=10 nM;
HRG=10 nM
Mean St. Dev. Kurt. Mean St. Dev. Kurt. Mean St. Dev. Kurt. Mean St. Dev. Kurt. Mean St. Dev. Kurt. Mean St. Dev. Kurt.
ERK* 5 min 0.0005 0.0057 3 0.0001 0.0011 50 0.0002 0.0020 7 0.0000 0.0008 148 0.0002 0.0018 10 0.0000 0.0008 152
ERK* 30 min 0.0001 0.0026 2 0.0002 0.0020 4 0.0002 0.0021 6 0.0000 0.0008 145 0.0001 0.0018 9 0.0000 0.0008 151
Akt* 5 min 0.0005 0.0078 11 0.0002 0.0046 12 0.0002 0.0042 12 0.0002 0.0034 12 0.0002 0.0043 12 0.0002 0.0034 12
Akt* 30 min 0.0002 0.0061 10 0.0003 0.0062 11 0.0002 0.0040 12 0.0002 0.0035 12 0.0002 0.0041 12 0.0002 0.0034 12
Abbreviations: Kurt., Kurtosis; St. Dev., Standard Deviation.
Rows correspond to ERK or Akt activation at either 5 or 30 min, whereas columns correspond to a particular ligand–dose combination and population statistic.
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Figure 5 Effect of various negative feedback loops on ERK and Akt activity. Plots correspond to complete inhibition of (A) PTP1-B, (B) ERK feedback to ErbB
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This suggests that HRG may stimulate more MEK activity than
is necessary to induce the observed peak ERK activation, and
led us to hypothesize that HRG-stimulated ERK activation
would be less sensitive to a MEK inhibitor (U0126) than would
EGF-stimulated ERK activation. We investigated this hypoth-
esis both computationally and experimentally, and the results
are shown in Figures 7A and B. As can be seen, both the
experimental data and model simulations show that EGF-
stimulated ERK activation is indeed more sensitive to U0126
than HRG-stimulated ERK activation. Although the model
slightly overpredicts the effect of U0126 on HRG-stimulated
ERK activation, the model simulations have excellent quanti-
tative agreement with the EGF data.
Ligand-dependent effects of the PI-3K inhibitor
wortmannin
To test further the predictive powers of our model, we
experimentally measured the effect of a PI-3K inhibitor,
wortmannin, on EGF- and HRG-induced ERK activation
over a 30-min time course (Figure 8A), and we compared
these data to the model predictions (Figure 8B). The model
correctly predicts several features of the experimental
data. First, we observe that wortmannin has significant effect
on post- but not pre-peak EGF-induced ERK activity. Impor-
tantly, this corroborates our previous prediction based on
sensitivity analysis. Second, for all time points less than
30 min, both the model and experiments show that wortman-
nin has a small effect on HRG-induced ERK activity. Third,
experiments and model simulations show that wortmannin
affects the magnitude of EGF-induced ERK signaling at times
greater than 5 min, but does not change the qualitative shape
of the response.
While there are several points of corroboration between
model predictions and experimental data in Figure 8, there are
also points of disagreement. The model underestimates the
effect of wortmannin on EGF-induced signaling at long times.
Also, the experimental data show that wortmannin causes
Figure 6 Effect of 10-fold ErbB2 overexpession. (A) Simulations of EGF- and HRG-induced ERK (left) and Akt activation (right) under wild-type (WT) and ErbB2
overexpression conditions. (B) Setting the on and off rates of PTP-1B for 1-1 and 1-2 receptors equal to each other causes ErbB2 overexpression to increase rather than
decrease EGF-induced peak Akt activation.
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HRG-induced signaling to become slightly transient at 30 min,
but the model does not show this. As mentioned and explained
above in ‘Dynamic and Dose Response of the ErbB Signaling
Network to EGF and HRG’, the model over estimates the
magnitude of EGF-induced signaling past 10 min.
While these discrepancies show that the model cannot
predict all the effects of wortmannin on ERK activation, they
give us direction as to how the model may be improved in
future studies. An attractive candidate for addition to the
model, which may help to explain these wortmannin data,
is the tyrosine phosphatase SHP2. SHP2 is recruited to Gab1
in response to ligand stimulation (Yart et al, 2001), but is
actually a positive regulator of ERK signaling due to its selec-
tive dephosphorylation of RasGAP binding sites on receptors
(Agazie and Hayman, 2003) and Gab1 (Montagner et al, 2005).
Thus SHP2 represents an additional PI-3K-dependent pathway
that positively affects ERK signaling.
Discussion
In the present work, we developed a quantitative kinetic model
that relates EGF and HRG stimulation of the ErbB receptors to
ERK and Akt activation in MCF-7 breast cancer cells. To our
knowledge, this is first model to take into account all four ErbB
receptors, simultaneous stimulation with two ligands, and
both the ERK and Akt pathways. In the context of this study,
we used this model to help gain mechanistic insight into
ligand-dependent responses of the ErbB signaling network.
When a mechanistic modeling approach is used to represent
the ErbB signaling network, combinatorial complexity makes
the modeling task infeasible. Rule-based modeling tools that
facilitate building combinatorially complex models have been
recently developed and promise to be valuable for dealing with
the complexity of signal transduction modeling (e.g. Blinov
et al, 2006). However, until current parameter identification
A
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Figure 7 U0126 Titration of 5 min ERK activation. (A) Immunoblots are representative of two independent experiments. U0126 concentrations are as follows: (0):
control; (1): 10 mM; (2): 5 mM; (3): 1 mM; (4): 500 nM; (5): 250 nM; (6): 125 nM; (7): 62 nM; and (8): 0 nM. (B) Comparison of the experimental U0126 titration and model
predictions. Error bars represent the range of the data. ERK activity for each ligand is normalized to its own control, and not a single reference point.
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and bifurcation analysis techniques are capable of handling
extremely large models generated by rule-based algorithms,
we should take steps to reduce combinatorially complex
models and make them mathematically tractable. As similar to
previously published models on ErbB signaling (e.g. Kholo-
denko et al, 1999), we represented the entire complement of
phosphorylated cytoplasmic receptor tyrosines as a ‘virtual
phosphorylation site’. We showed a subtle yet important
consequence of this assumption: when a protein binds to
multiple locations on the receptor tail, the on-rate should
be multiplied by the number of locations. We introduce
the concept of membrane-localized ‘S-states’, where we
assume that the action of membrane recruited proteins can
be decoupled from its path to the membrane. Although all
these assumptions impose approximations, they also make the
modeling exercise computationally tractable. As the model
reflects the measured system dynamics reasonably well and
gives insight into the differences in ligand-dependent signaling,
the assumptions seem reasonable for the analysis carried out.
To begin to understand the behavior of this complex system,
and specifically how peak and long-time ERK and Akt
activities are regulated, we employed sensitivity analysis
and in silico inhibition studies. In general, such modeling
analyses are indispensable for generating hypotheses as to
how quantities of interest are controlled in complex dynamic
systems. Naturally, these analyses revealed many obvious
modes of regulation, for instance, control of Akt activation by
PIP2/PIP3 reaction parameters and control of ERK activation
by Ras, Raf, and MEK reaction parameters. However, these
modeling analyses also revealed non-obvious modes of
potential regulation: (i) ERK activation is robust to parameter
perturbation at high ligand doses, whereas Akt activation
is not and (ii) PI-3K is a dominant factor for long-term but
not short-term EGF-induced ERK activation. Analysis of the
multiple negative feedback loops revealed specialized roles for
each feedback in regulating ERK and Akt activity at different
time points and dose combinations. By combining logical
reasoning with simulation analysis, these observations led to
many new insights as to how the ErbB signaling network
functions in MCF-7 cells, such as the signaling specificity of
different ErbB dimers and robustness of signaling responses.
Investigating all of these hypotheses experimentally is outside
the scope of a single study. However, over time the combined
results of many studies can be used to test these hypotheses,
and when conflicts arise, revise our model and understanding
of the ErbB signaling network.
We also used the model to generate hypotheses about a
specific topic of known relevance: the effect of ErbB2
Figure 8 Effect of wortmannin on EGF- and HRG-induced ERK activation dynamics. (A) Immunoblots are representative of three independent experiments.
Wortmannin concentration used was 100 nM. (B) Data are normalized as described in Materials and methods, to the 5 min no wortmannin point. Error bars correspond to
standard deviations.
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overexpression on ErbB network signaling. Our analysis
revealed that while ErbB2 overexpression should have a small
effect on HRG-induced signaling, it has causes EGF-induced
signaling to become more sustained. The prediction that ErbB2
overexpression will sustain EGF-induced ERK signaling is
corroborated by studies of ErbB2 overexpression in HMECs,
which showed that at 10 and 30 min after EGF stimulation,
ERK activation is between 1.15- and 2-fold higher for cells
overexpressing ErbB2 (Wolf-Yadlin et al, 2006; Kumar et al,
2007). The current hypothesis to explain the sustainment of
EGF-signaling is that ErbB2 overexpression causes a higher
proportion of 1-2 heterodimers rather than 1-1 homodimers
to be activated upon ligand stimulation, and as only 1-1 homo-
dimers undergo ligand-induced internalization, this over-
expression sustains signaling. While Sorkin et al (1993) and
Baulida et al (1996) were among the first to show the
preferential retention of ErbB2-containing heterodimers on
the plasma membrane, recent experimental studies also
support this hypothesis. Haslekas et al (2005) showed that
ErbB2 inhibits internalization of EGF bound to ErbB1 by
driving heterodimerization. Lynch et al (2004) reported that
internalization defective ErbB1 mutants commonly found in
ErbB1-kinase-inhibitor-responsive non-small cell lung cancers
display sustained signaling in response to EGF. Hendriks et al
(2005) showed that 184A1 HMECs with high ErbB2 expression
had more sustained EGF-induced ERK activity compared to
ERK responses from the same cell line with low ErbB2
expression. Furthermore, their modeling results imply that
this difference may be due to ErbB2-induced alterations in
ErbB1 receptor trafficking. Overall, our model predictions and
the corresponding literature lend insight into potential reasons
why ErbB2-overexpressing or ErbB1 internalization-defective
mutants are found in cancer.
We also investigated a hypothesis resulting from prelimin-
ary examination of the experimental data and model simula-
tion results: the differential sensitivity of EGF- and HRG-
stimulated ERK activity to the MEK inhibitor U0126. The
model predicted that HRG-stimulated ERK activity would be
less sensitive to U0126 than the EGF-stimulated activity, and
this result was confirmed experimentally. This result is also
consistent with the experimental studies of Thottassery et al
(2004), who found that HRG but not EGF reduced the negative
effect of U0126 on proliferation and on ERK activation in MCF-
7 cells. Additionally, the model had excellent quantitative
agreement for EGF signaling, but slightly overpredicted the
effect of U0126 on HRG signaling. It may be possible that
mechanisms not incorporated into the model, such as the ERK
cascade scaffolds KSR and MP1 or B-Raf, which most likely
decrease the sensitivity of the ERK cascade to inhibition, may
be able to account for the HRG discrepencies.
While our model is able to correctly predict many features of
ligand-dependent ErbB signaling, we also found limitations to
predict all the effects of wortmannin on ERK signaling. The
current model correctly predicted that post-peak but not pre-
peak EGF-induced ERK signaling should be sensitive to a PI-3K
inhibitor, but underestimated the post-peak effects of wort-
mannin on EGF- and HRG-induced ERK signaling. This lack of
agreement between the model predictions and experimental
data is not entirely unexpected, as all models have limitations.
These limitations suggest where the model needs to be
refined and improved in future studies. The incorporation
of the tyrosine phosphatase SHP2 is a logical next step to
help explain these wortmannin effects, as SHP2 is a PI-3K-
dependent positive regulator of ERK signaling. Incorporation
of SHP2 is a significant modeling undertaking, however, as
SHP2 selectively dephosphorylates RasGAP-binding sites on
Gab1 and ErbB receptors and its addition will require descrip-
tion of individual phosphorylation sites, as opposed to virtual
phosphorylation sites. Such a description will require further
development of novel reduction methods to keep the model
tractable.
Studies similar to the current work hold the potential to
complement the field of targeted cancer treatment. Currently,
many ErbB-targeted pharmaceuticals are clinically used to
treat cancer, including the small molecule ErbB1 kinase
inhibitors erlotinib and gefitinib (Harari and Huang, 2006),
and a monoclonal ErbB2 antibody, trastuzumab (Adams and
Weiner, 2005). Although correlation analyses have provided
insight as to when these pharmaceuticals will be effective,
there is still much work to be done to determine when to use
these pharmaceuticals, and in what combinations. A computa-
tional model of the ErbB signaling systems in the cancer type of
interest can help predict factors that could guide the choice of
when to use a particular targeted pharmaceutical, and in what
combinations. As a simple example, we saw in the current
analysis that for an ErbB2-overexpressing cancer, if ErbB1
homodimers do not undergo ligand-induced degradation, then
inhibiting ErbB2 with a drug such as trastuzumab may have
minimal effect on EGF-induced signaling. More generally, the
results of sensitivity analysis can be used to conjecture the
critical determinants of signaling behavior, and thus give
potential drug targets. A multivariate, global sensitivity
analysis could give insight into the drug combinations that
may work synergistically.
Materials and methods
Cell culture and western blots
The MCF-7 human breast cancer cell line was obtained from American
Type Culture Collection (ATCC) and maintained in DMEM (Gibco BRL,
Githersburg, MD) supplemented with 10% fetal bovine serum. Before
growth hormone treatment, the cells were synchronized by serum-
starvation for 16–24 h, and then EGF (PeproTech House, London,
England) or HRG-b176-246 (R&D Systems Inc., Minneapolis, MN) was
added. In experiments that involved U0126 (Calbiochem, San Diego,
CA) treatment, the inhibitor was added 20 min before growth hormone
treatment. Cells were incubated with the growth hormone in the
presence or absence of kinase inhibitors for the indicated period of
time, washed three times with phosphate-buffered saline (PBS), and
lysed with Bio-Plex lysis buffer (Bio-Rad laboratories, Hercules, CA).
Cell lysate was cleared by centrifugation, and the total protein
concentration of the supernatant was determined using a protein assay
reagent. Lysates were normalized to the same total protein concentra-
tion by dilution. Gel electrophoresis and western blotting were
performed as described previously (Hatakeyama et al, 2003). Anti-
bodies against doubly phosphorylated p44/42 ERK, ERK, phospho-Akt
(Ser473), Akt, phospho-MEK1/2 (Ser217/221), and MEK were pur-
chased from Cell Signaling Technology Inc. (Beverly, MA), anti-
phospho-Shc (Tyr317) and anti-Shc antibodies were purchased from
Upstate Biotechnology (Lake Placid, NY), and all anti-ErbB receptor
antibodies and anti-phosphotyrosine antibody (PY20) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). To detect ErbB
receptor phosphorylation, the total cell lysate was immunoprecipitated
with the corresponding ErbB antibodies, and immunoblotted with anti-
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phosphotyrosine antibody (PY20, Santa Cruz Biotechnology). Protein
band intensities were quantified using a densitometer (Fuji Film Corp.,
Japan). To analyze a large set of samples at a time, as required with the
dual-ligand stimulation experiments, we used the Bio-Plex Suspension
Assay System (Bio-Rad Laboratories) to detect phosphorylated and non-
phosphorylated forms of ERK and Akt. We previously confirmed that
the data obtained from the Bio-Plex assay are reproducible and correlate
well with western blot data in our cell system (unpublished data).
Model development
From the kinetic scheme (Figure 2), which describes the connectivity
of the reaction network, a deterministic ODE model was derived using
the law of mass action and saturating rate laws to describe the
corresponding reactions. The rate of change of a species concentration
with time (time derivative) is calculated by summing all reaction rates
that produce this species and subtracting all reaction rates that
consume this species. When a reaction involves species whose
concentrations are defined in compartments different from where
the reaction is taking place, these species concentrations are rescaled
to reflect the reaction compartment volume, and the reaction rate is
calculated based on the rescaled species concentrations. The species
concentrations are rescaled back to the reference compartment volume
for calculating the rate of change. The cytoplasm is chosen as the
reference compartment in this study. Details about the rate laws
and parameter values can be found in the Supplementary information
online.
Model fitting & simulation
Fitting & simulation was carried out with MATLAB 7.0 Serivce Pack 2
software (The Mathworks; Natick, MA) on AMD 64 Dual Core 2.0 GHz
processor computers running CENTOS 4.4 linux (www.centos.org).
Differential equations were integrated using the function ode15s,
which is a variable order solver, based on the numerical differentiation
formulas (NDFs) and is designed for stiff systems. Local minimization
was carried out with the function lsqnonlin, which is a subspace
trust region method and is based on the interior-reflective Newton
method. Details of the parameter estimation can be found in the
Supplementary information online.
Normalization of experimental data for direct
comparison with model simulations
Several normalization steps were taken to make quantitative
immunoblot data (relative concentrations) compatible with data from
model simulations (absolute concentrations). First, all experimental
data were divided by their respective control intensity. Second, all data
collected from the same experiment/blot were divided by a normal-
ization point, chosen to be the largest intensity point. This normal-
ization point is chosen in favor of the zero point, because there is less
uncertainty associated with more intense signals (higher signal to
noise ratio). Lastly, the zero point from each blot is subtracted from
every data point collected from that blot.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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